U.S. markets closed

Aspira Women's Health Inc. (AWH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.9500+0.1000 (+2.06%)
At close: 4:00PM EDT

4.9100 -0.04 (-0.81%)
After hours: 4:07PM EDT

Aspira Women's Health Inc.

Building III
Suite 100 12117 Bee Caves Road
Austin, TX 78738
United States
512 519 0400

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Valerie Barber PalmieriCEO, Pres & Director544.43kN/A1961
Mr. Robert Harry Beechey CPAChief Financial Officer364.68kN/A1963
Ms. Kaile ZaggerChief Operating OfficerN/AN/AN/A
Dr. Lesley Northrop Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Emily GrangerDirector of MarketingN/AN/AN/A
Ms. Elena Ratner M.D.Global Chief Medical Advisor of Clinical & Translational MedicineN/AN/AN/A
Mr. Gary Altwerger M.D.Global Deputy Chief Medical Advisor of Clinical & Translational MedicineN/AN/AN/A
Ms. Diane Powis Ph.D.Chief SpokeswomanN/AN/AN/A
Mr. Tom GrecoHead of Strategic Corp. Devel. & ExpansionN/AN/AN/A
Ms. Stephanie SwensonControllerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Corporate Governance

Aspira Women's Health Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.